Efficacy of pain treatment on mood syndrome in patients with dementia: a randomized clinical trial by Husebø, Bettina Sandgathe et al.
Efﬁcacy of pain treatment on mood syndrome in patients
with dementia: a randomized clinical trial†
B. S. Husebo1,2, C. Ballard2,3, F. Fritze1,2, R. K. Sandvik1 and D. Aarsland2,4
1Department of Global Public Health and Primary Care, Center for Elderly- and Nursing Home Medicine, University of Bergen, Bergen,
Norway
2Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
3The Wolfson Wing & Hodgkin Building Guys Campus, Kings College, London, UK
4Karolinska Institute (KI), Department of Neurobiology, Care Sciences and Society, KI-Alzheimer Disease Research Center, Novum,
Stockholm, Sweden
Correspondence to: B. S. Husebo, E-mail: Bettina.Husebo@isf.uib.no
†This article was published online on 19 December 2013. An omission from the Acknowledgements section was subsequently identiﬁed. This notice is included in the online and
print versions to indicate that both have been corrected [7 July 2014]
Background:Depression is common in nursing home (NH) patients with dementia, and often clustered
with anxiety and other mood symptoms. An association between pain and depressive symptoms has
been reported, but the impact of pain management on depression and other mood symptoms has
not been investigated.
Objective: Secondary analyses of a cluster randomized clinical trial examine the response of
dementia-related mood symptoms to a Stepwise Protocol of Treating Pain.
Method: Three-hundred ﬁfty-two patients with moderate and severe dementia and signiﬁcant behav-
ioural disturbances, related to 60 clusters (i.e. clusters deﬁned as single independent NH units) in 18
NHs of Western Norway, were included. All patients in the intervention group received individual daily
pain treatment with paracetamol, extended release morphine, buprenorphine transdermal patch or
pregabaline for 8weeks, with additional follow-up assessment 4 weeks after completion of the
intervention. Clusters randomized to control received usual treatment. A mood cluster consisting of
depression, anxiety, sleep disorders, apathy and appetite items from the Neuropsychiatric
Inventory-Nursing Home (NPI-NH) was the primary outcome.
Results: Analysed by Mann–Whitney U-tests, Stepwise Protocol of Treating Pain conferred signiﬁcant
beneﬁt in treatment of the NPI-NH mood cluster (F= 13.4, df= 1;299, p< 0.001) and depression
(F= 2.0, df= 1;301, p= 0.025). Further analyses highlighted improvements in apathy (F= 5.3, df= 1;300,
p= 0.017), night-time behaviours (F= 3.1, df= 1;301, p= 0.050), and appetite items (F= 11.6, df=
1;301, p= 0.005), but not irritability (p= 0.092) and anxiety (p= 0.125).
Conclusion: Mood symptoms including depression signiﬁcantly improved with pain treatment,
emphasizing the importance of more rigorous treatment of pain in agitated people with dementia.
Findings have potentially immediate clinical relevance. # 2013 The Authors. International Journal of
Geriatric Psychiatry published by John Wiley & Sons Ltd.
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Introduction
In nursing homes (NH), 80% of the patients have
dementia, and of them, 90% have one or more neuro-
psychiatric symptoms (NPSs) (Selbaek et al., 2008).
The most frequently occurring of the NPS are depres-
sion, apathy and anxiety (Robert et al., 2005). The
prevalence of these symptoms differs in accordance
to the diagnoses and severity of dementia. In patients
with Alzheimer’s disease, about 50% will have
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depressive symptoms at some stage of the disease
(Lyketsos and Olin, 2002). In vascular dementia, depres-
sion is expected at least as common as in Alzheimer’s
dementia (Ballard et al., 2000). In Norwegian NHs,
depressive symptoms occur in about 21% of all patients,
with follow-up incidence of 14.9% and persistence rate
44.8% after 1 year (Selbaek et al., 2008).
Although depressive symptoms might ﬂuctuate
over time, depression hastens cognitive decline (Rapp
et al., 2011), has a negative impact on the quality of life
(St John and Montgomery, 2010) and worsens
functional impairment (Starkstein et al., 2005). Other
mood disorders such as apathy, anxiety, nigh-time
behaviours and appetite and eating disorders are less
well studied but also frequent and impactful in these
individuals (Aalten et al., 2003; Hollingworth et al.,
2006; Wetzels et al., 2010). Thus, the ﬁve-year preva-
lence of apathy and anxiety is about 70 and 60%,
respectively (Steinberg et al., 2008), whereas nigh-time
behaviours, and appetite and eating disorders increase
to over 40% in patients with severe dementia
(Craig et al., 2005).
As in non-demented populations, depressed mood is
usually accompanied by other related symptoms. This is
also reﬂected in the proposed diagnostic criteria for
depression in Alzheimer’s disease, which in addition to
the core symptoms depressed mood and anhedonia,
also includes symptoms such as disturbance of sleep
and appetite (Olin et al., 2002). Similarly, several studies
have found that NPSs tend to cluster into broader
syndromes such as agitation, psychosis and mood
syndromes (Aalten et al., 2003; Hollingworth et al.,
2006; Wetzels et al., 2010; Cheng et al., 2012; Selbaek
and Engedal, 2012). Additionally, a prevalence study
focussing on patients in psychogeriatric wards of Dutch
NHs reported that irritability was one of the most
prominent features of depression in people with
dementia (Verkaik et al., 2009).
Antidepressants have been the usual treatment for
patients with depressive symptoms and dementia.
However, systematic reviews and meta-analyses could
not ﬁnd beneﬁt of the treatment (Bains et al., 2002;
Thompson et al., 2007; Nelson and Devanand, 2011).
Two most recent and larger trials of antidepressants
did not conﬁrm the efﬁcacy of antidepressants
compared with placebo but increased the risk of adverse
events in the intervention group in depressed people
with dementia (Weintraub et al., 2010; Banerjee et al.,
2011). Another large-scale study found that selective
serotonin reuptake inhibitors were associated with
signiﬁcant higher rates of all-cause mortality, stroke,
falls or fractures (Coupland et al., 2011). Despite these
results, antidepressants are frequently used in NH
residents with dementia (Ruths et al., 2012). Thus, there
is an urgent need for new and improved treatment
strategies to contribute to the management of depres-
sive symptoms in people with dementia.
The aetiology of depressive symptoms in dementia
is largely unknown. However, in addition to brain
changes such as white-matter lesions, unmet psycho-
logical needs such as pain may be associated with in-
creased NPSs in patients with dementia (Ballard
et al., 2009). Although few studies have explored such
relationship (Ballard et al., 1996), it was suggested that
patients with moderate dementia and pain express the
highest levels of depression (Cohen-Mansﬁeld and
Taylor, 1998), and that moderate dementia exacerbate
the impact of pain on depression in NH patients and
elderly people living at home (Walid and Zaytseva,
2009). Therefore, it is a key question whether pain
treatment could improve depression and other mood
symptoms in patients with advanced dementia.
The purpose of this study was to examine the effect
of a Stepwise Protocol of Treating Pain (SPTP) on the
two primary outcome measures of the composite
mood syndrome scores and the depression item
assessed by the Neuropsychiatric Inventory-Nursing
Home version (NPI-NH) (Cohen-Mansﬁeld and
Libin, 2004). Secondary outcome measures were the
other items included in the mood syndrome, that is,
apathy, anxiety, night-time behaviours and appetite
and eating disorders. In addition, the effect of the
SPTP on irritability was investigated.
Methods
Subjects
Nine-hundred-forty patients of 18 NHs on the West
coast of Norway were screened for participation in
the study. The original pool of participants consisted
of 420 patients with moderate and severe dementia
and signiﬁcant behavioural disturbances. Data collec-
tion was performed October 2009 to June 2010. The
recruitment strategy, patient samples and design of
this study have also been described elsewhere (Husebo
et al., 2011). In brief, eligible participants were adults
≥65 years, living in the NH for at least 4 weeks, with
moderate or severe dementia according to Diagnostic
and Statistical Manual of Mental Disorders, fourth edi-
tion, Functional Assessment Staging score>4 (Reisberg,
1988), and clinical relevant behavioural disturbances
deﬁned as Cohen-Mansﬁeld Agitation Inventory score
≥39 (Cohen-Mansﬁeld and Libin, 2004). Exclusion
criteria were advanced medical disease with expected
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survival ≤6months, severe psychiatric or neurological
disorders (NPI-NH agitation score ≥8, with aggression
as predominant symptom) (Selbaek et al., 2007), and
allergy to paracetamol, extended release morphine,
buprenorphine or pregabaline. The ﬁnal sample included
352 participants (Husebo et al., 2011).
Ethics
Written informed consent included a description of the
study design, direct beneﬁt and possible side effects of
the trial. Because individuals with mild cognitive
impairment have an impaired capacity to consent to
research (Ayalon, 2009), informed consent was
obtained from all patients, and all surrogates/caregivers
or the authorized legal representative. In accordance
with local law, the study was approved by the Regional
Committee for Medical Ethics, Western Norway
(REK-Vest 248.08) and by the authorized Institutional
Review Board of each participating institution. Care-
givers also give consent to participate as informants.
Study design
This was a cluster randomized controlled trial for
8weeks (treatment period) with an additional follow-
up 4weeks after the end of treatment at 12weeks
(wash-out period) to see whether symptoms reappeared
after treatment withdrawal. A cluster was deﬁned as
single independent NH unit. Thus, patients related to
the clusters were randomly assigned to receive SPTP in
the intervention group or continued with their usual
management (control group). A computer-generated
list of random numbers was used for allocation of the
clusters by the study statistician using Stata version
8 (StataCorp LP). Patients were examined at baseline
and 2, 4 and 8week, as well as at the end of the wash-
out period at week 12. The treating physicians were
instructed to keep prescriptions and doses of psychotro-
pic medications unchanged, and none of the patients
started with antidepressants during the 8-week period.
Procedure
The research group, consisted of an anaesthetist and
pain therapist (B. S. H), a research assistant (R. K. S.),
the responsible NH physician and the patient’s
primary caregiver, investigated each single patient.
Together with the patients’ primary care givers, two
trained research assistants retrieved data pertaining
to background variables, which included information
about sex, age, medical information (diagnoses, and
pain diagnoses) and list of medication taken. Attempts
were made to keep the patients, the primary care
givers and the research assistants blinded about the
study design and type of intervention.
Outcome measures
The NPI-NH is a 12-item instrument to assist care-
givers to rate the frequency and severity with which
NH patients manifest NPSs (Selbaek et al., 2007).
The rating was made by a trained research assistant
based on a face-to-face interview with the caregiver
who was familiar with the patient.
Neuropsychiatric Inventory-Nursing Home items
are rated on a 1 to 4 point scale of frequency, ranging
from (1) Occasionally—less than once per week; (2)
Often—about once per week; (3) Frequently—several
times a week but less than every day; (4) Very fre-
quently—daily or essentially continuously present.
The severity is rated as (1) Mild—produce little dis-
tress in the patient; (2) Moderate—more disturbing
to the patient but can be redirected by the caregiver;
(3) Severe—very disturbing to the patient and difﬁcult
to redirect. For each item a composite score is calcu-
lated as frequency (F) × severity (S), with a maximum
score = 12. Dependent items are present or absent by a
cut-off F× S< or≥ 4. Good validity and reliability of
the Norwegian version of the NPI-NH has been
reported (Selbaek et al., 2007).
The two primary outcome measures in the current
study were the depression item and the composite
mood syndrome scores. Secondary outcome measures
were the other items included in the mood syndrome,
that is, apathy, anxiety, night-time behaviours and
appetite and eating disorders (Olin et al., 2002; Cheng
et al., 2012). The effect of treating pain on irritability
was also determined as a further exploratory analysis
(Verkaik et al., 2009).
Pain was assessed by the Mobilization-Observation-
Behaviour-Intensity-Dementia-2 (MOBID-2) Pain Scale,
a staff-administered observational pain behaviour assess-
ment instrument, developed and tested in NH patients
with advanced dementia (Husebo et al., 2010).
Intervention
The SPTP was based on the recommendations of the
American Geriatrics Society (AGS Panel, 2009).
Depending on the on-going medical treatment,
participants received paracetamol oral (max. increase
to 3 g/day), extended release morphine oral (max.
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20mg/day), and/or pregabaline oral (max. 300mg/d)
using a ﬁxed dose regime. Patients with swallowing
difﬁculties were treated with buprenorphine trans-
dermal patch (max. 10 ųg/h/7 days). Medication
was offered at breakfast, lunch and dinner (appro-
ximately 8:00 AM, noon, 6:00 PM), respectively. If
needed, it was allowed to combine different medi-
cations. In patients who were not able to tolerate
this treatment, the dosage was reduced or the
patient was withdrawn from study and treated as
clinically appropriate.
Statistical analysis
Demographic and clinical characteristics between the
control and intervention group at baseline were
compared using chi-square for categorical variables,
Independent-Samples T-test for normal and Mann–
Whitney U-test for non-normal distributed continu-
ous variables. In addition, Mann–Whitney U-test was
used to investigate the inﬂuence of pain treatment on
the composite mood syndrome scores (depression,
apathy, anxiety, night-time behaviours and appetite
Figure 1 Study ﬂow diagram.
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and eating disorders), and to address whether the
change in depressive symptoms at week 8 is associated
with the use of antidepressants. Additionally, the anal-
gesic effect on irritability was investigated. To explore
whether the improvement in mood syndrome and the
other items were associated with reduced pain, we
correlated the change scores in these items with
change scores in pain using Spearman rho correlation.
Treatment effect was expressed as estimated effect of
intervention, along with a 95% conﬁdence interval and
the p-values for each time point. p-values less than 0.05
were considered as statistically signiﬁcant. Standardized
effect sizes (ES) were calculated as mean change divided
by the baseline standard deviation (SD). For clinical
relevance, the size of ES is conventionally classiﬁed as
being large (0.5), moderate (0.3) or small (0.1) (Field,
2005). Statistical analyses were performed using the
software program SPSS 13.0 (SPSS, Inc., Chicago, IL).
Results
Three-hundred ﬁfty-two patients in 60 clusters
were ﬁnally randomized (177 patients in the control
and 175 in pain treatment group) (Figure 1); 170
patients in the control and 171 in the intervention
group were assessed by NPI-NH at baseline.
Demographic and clinical characteristics at baseline
are shown in Table 1. The intervention group was
slightly younger and with a smaller proportion on
Table 1 Background characteristics of patients at baseline for the control and intervention group
Control
(n=177)
Intervention
(n=175)
Statistics
df p
Agea 86.5 (6.7) 84.9 (7.0) 1;350 0.022
Femaleb 131 (74.0) 131 (74.9) 1 0.856
MMSEa 8.4 (6.7) 7.5 (6.4) 1:346 0.209
NPI-NH total scorec 31.4 (21.4) 34.8 (21.9) 1;339 0.143
NPI-NHc—mood cluster 16.3 (12.5) 18.3 (13.0) 1;340 0.291
NPI-NHc—depression 2.8 (3.6) 2.8 (3.5) 1;341 0.902
NPI-NHc—apathy 2.5 (3.6) 3.5 (4.2) 1;341 0.041
NPI-NHc—anxiety 3.1 (4.0) 3.4 (4.2) 1;341 0.481
NPI-NHc—irritability 3.7 (3.7) 4.2 (4.1) 1;341 0.338
NPI-NHc—sleep 2.2 (3.2) 1.9 (3.2) 1;341 0.295
NPI-NHc—appetite 2.5 (4.0) 2.5 (4.1) 1;341 0.884
Antidepressantsb 94 (56.2) 74 (42.5) 1;341 0.013
Antipsychoticsb 91 (54.5) 86 (49.4) 1;341 0.386
Numbers represent mean (SD) or number of patients (%).
MMSE, Mini-mental status examination; NPI-NH, Neuropsychiatric Inventory-Nursing Home version.
aIndependent-Samples T-test.
bPearson Chi-square (test statistics).
cMann-Whitney U-test.
Table 2 Efﬁcacy of pain treatment for single Neuropsychiatric Inventory-Nursing Home version item scores, the mood syndrome factor group and
irritability, mean (SD) at baseline and week 8 for the control and intervention groups
Baseline Week 8
Control
(n=170)
Intervention
(n=171)
p-
valuea
Control
(n=156)
Intervention
(n=142)
p-
valuea
NPI-NH total score 31.9 (21.9) 33.8 (21.7) 0.132 26.6 (20.1) 18.9 (17.6) <0.001
Mood symptom factor group 16.9 (12.5) 18.3 (13.0) 0.291 14.7 (11.5) 9.9 (10.6) <0.001
Depression 2.9 (3.7) 2.5 (3.3) 0.902 2.1 (2.9) 1.6 (2.9) 0.025
Anxiety 3.2 (4.1) 3.3 (4.2) 0.481 2.5 (3.7) 1.8 (3.1) 0.125
Apathy 2.5 (3.6) 3.6 (4.3) 0.041 2.6 (3.7) 1.7 (3.3) 0.017
Irritability 3.7 (3.7) 4.2.(4.1) 0.388 2.9 (3.4) 2.3 (3.0) 0.092
Night-time behaviours 2.2 (3.3) 1.6 (2.7) 0.295 1.9 (3.1) 1.3 (2.6) 0.050
Appetite and eating disorders 2.5 (4.0) 2.4 (4.1) 0.884 2.7 (4.0) 1.3 (2.9) 0.005
NPI-NH, Neuropsychiatric Inventory-Nursing Home version.
aAnalyzing the factor group scores for the control versus the intervention group from baseline to week 8 using Mann-Whitney U-test.
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antidepressants than the control group, but the two
groups did not differ in depression scores at baseline.
During the 8weeks, 20 and 28 patients were lost in
the control and intervention group, respectively
(p= 0.298) (Husebo et al., 2011). There were 14 deaths
during the study period, eight in the control and six in
the intervention group.
High prevalence rates were shown for depression
(34%), anxiety (38%), apathy (37%), irritability
(32%), sleeping and night-time behaviours (25%),
and appetite and eating disturbances (28%). Table 2
and Figure 2 show the change on the composite mood
syndrome scores, depression and the other items. The
depression and composite mood scores declined in
both groups. However, the changes of both the
primary outcome measures differed signiﬁcantly be-
tween the two groups in favour of pain treatment:
composite mood syndrome (F= 13.4, df= 1;299,
p< 0.001, ES = 0.6), and depression item (F= 2.0, df=
1;301, p= 0.025, ES = 0.3). Changes over the treat-
ment period (week 0–12) are shown in Figure 2.
Similarly, signiﬁcant differences were found for the
Figure 2 Change in the pain treatment and control groups in the mood syndrome factor group (depression, anxiety, apathy, irritability, night-time
behaviours and appetite and eating disorders) and on single items of the Neuropsychiatric Inventory-Nursing Home version compared with control
group and mean values at baseline, week 2, 4, 8 and 12.
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secondary variables, apathy (F=5.3, df=1;300,
p=0.017, ES= 0.6), night-time behaviours (F=3.1, df=
1;301, p=0.050, ES= 0.1), and appetite and eating dis-
orders (F=11.6, df=1;301, p=0.005, ES= 0.4),
whereas the difference on irritability (F=2.0, df=1;301,
p=0.092, ES= 0.3) and anxiety (F=3.0, df=1;300,
p=0.125, ES= 0.5) did not reach statistical signiﬁcance.
After 8weeks, change scores of the composite mood
syndrome were found to be signiﬁcantly correlated to
change in pain (Spearman rho= 0.147, p= 0.012). In
addition, the change scores of depression, apathy and
irritability were correlated with change in pain (rho =
0.127, p= 0.030; rho = 0.154, p= 0.008; rho = 0.182,
p= 0.002), respectively. The pain treatment effect on
change scores of depression was independent ongoing
antidepressant therapy (p= 0.466) in the intervention
group at week 8.
Discussion
Analyses of an RCT study indicate that stepped pain
treatment confers signiﬁcant beneﬁts on the composite
mood syndrome in NH patients with dementia and
agitation. Results support the idea that undiagnosed
and untreated pain are important cofactors in the gene-
sis of distressing mood symptoms such as depression,
apathy, night-time behaviours and appetite and eating
disorders. Reduction of pain in the treatment group
after 8weeks was correlated with change scores of the
composite mood syndrome, depression, apathy and ir-
ritability ﬁndings support the hypothesis that the
reduction of these symptoms was indeed secondarily
related to reduced pain.
Analyses underline earlier assumptions that depres-
sive symptoms in patients with dementia is at least
partly caused by pain, and thus large-scale placebo-
controlled studies to investigate the beneﬁt of pain
treatment on depression are warranted. Our results
parallel research with younger age groups, in which
there is a high occurrence of depression in chronic
pain samples and even without organic basis for the
pain (Casten et al., 1995). Moreover, depression is de-
scribed to be strongly related to pain in individuals
with cancer (Kirkova et al., 2010). Although these in-
teractions of comorbidities are accepted in general,
this link has surprisingly seldom been investigated in
NH patients with dementia (Ballard et al., 1996).
Our study corroborates and extends prior research
showing high apathy rates among patients with ad-
vanced dementia (Landes et al., 2001). At baseline,
we found apathy directly correlated to reduced activi-
ties in daily living (p< 0.001) and to musculoskeletal
pain assessed by MOBID-2 Pain Scale (part 1)
(Husebo et al., 2010) (p= 0.042). Thus, ﬁndings of this
study suggest that apathy may improve during pain
treatment in patients with dementia. Although studies
of apathy have been hampered by problems of deﬁni-
tion, apathy is often described as a loss of motivation,
interest and social engagement (Landes et al., 2001).
Combined with pain, apathy seems to provoke a symp-
tom spiral, which leads to the question whether pain in-
creases apathy or apathy increases pain by inactivity and
reduced mobilization. Family and staff may misinter-
pret apathetic patients as withdrawn, uninterested or in-
sensitive (Casten et al., 1995). Thereby, evaluation of
pain is a prerequisite to engage patients in rehabilita-
tion, and physical and social activities.
In the current study, anxiety was signiﬁcantly
correlated to depression (p< 0.001), pain (p=0.016),
and sleeping and night-time behaviours (p< 0.001), at
baseline. However, the change between the control and
intervention groups did not differ during the 8weeks. It
might be speculated that increased attention and regular
assessment and observation improved patients’ anxiety
and the overall judgement by staff. Although no treat-
ment studies for anxiety in older adults or patients with
dementia is available for direct comparison, data from
cross sectional observational studies suggest an anxiety–
pain interaction (Karp et al., 2008). In one study, anxiety
was the only signiﬁcant predictor of pain in a sample of
patients over the age of 65 years receiving inpatient reha-
bilitation after orthopaedic surgery (Casten et al., 1995).
Although some researchers exclude night-time behav-
iours and appetite and eating disturbances from their
analyses based on a 10-item NPI (Cheng et al., 2012), we
investigated the pain treatment effect because these
symptoms are frequent in NH patients with advanced de-
mentia and may be closely related to pain and depression.
In the current study, individuals with night-time behav-
iours were more in pain (p=0.032), and used more anti-
psychotics (p< 0.001) and antidepressants (p=0.040)
compared with those without sleeping disorders.
Although not included in the suggested mood
syndrome in dementia factor developed by Olin et al.,
(2002), more recent work has highlighted the impor-
tance of irritability as part of the depression in dementia
syndrome (Verkaik et al., 2009), and the identiﬁed
improvement in irritability with analgesic treatment is
therefore notable.
In contrast to the results from another publication
using the Cohen-Mansﬁeld Agitation Inventory
(Husebo et al., 2011), we could not ﬁnd worsening of
themood symptoms during the 4-week wash-out phase.
This is interesting and raises the question whether the
NPI-NH is less sensible to assess changes in NPSs. A
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more speciﬁc instrument such as the Cornell Scale for
Depression in Dementia (Barca et al., 2010) should be
used in future research. Interestingly, change scores in
mood were signiﬁcantly but modestly correlated with
change scores in pain. It is likely that the impact of an-
algesic treatment on mood is therefore multifactorial,
and may include mechanisms not directly related to an-
algesia. As noted earlier, opioids may have an antidepres-
sant effect in patients with affective disorders and
refractory depression (Schaffer et al., 2007). In one
study, the antidepressant effect of the partial antagonist
buprenorphine was noticed in patients with bipolar
disorders (Bodkin et al., 1995). However, no studies
have investigated the affective response on analgesics
in patients with advanced dementia.
Limitations
Several limitations of this study deserve comments, in-
cluding the use of treatment as usual instead of placebo.
We attempted to keep raters blind to the study objective
and treatment, but double-blind, placebo-controlled
studies of the effect of pain treatment on depression in de-
mentia are required.
This article reports secondary analyses of a cluster
randomized trial conducted for hypothesis generation
purpose. Thereby, more detailed cluster variation
(ICC) analyses to control for cluster effects have not
been included. This should be acknowledged as an im-
portant consideration in the interpretation of the data.
Further, we used a composite mood syndrome fol-
lowing conﬁrmatory factor analyses of a most recent
study by Cheng et al., 2012. However, factor groups
may be viewed as merely theoretical constructs with
uncertain clinical relevance and changes assessed over
time (Selbaek and Engedal, 2012).
Analyses are based on primary inclusion criteria
focusing on patients with agitation, and not on mood.
Thus, we can only conclude that mood syndrome in
people with advanced dementia and agitation seem
to beneﬁt from pain treatment, whereas future studies
should test whether pain treatment can reduce
depression in the dementia population.
In addition, the accuracy of proxy pain assessment
may be impact by dementia-associated behavioural
changes. For instance, high levels of depression may be
associated with increased likelihood of pain rating
because the patient’s facial expression seems to be sad
and worried. Thus, psychological symptoms like depres-
sion, anxiety and apathy, which also may be related to
unmet needs such as grief, social isolation or soiled dia-
per may be misunderstood as pain (Corbett et al., 2012).
Conclusion
This study investigated a simple question: has a
stepwise protocol of treating pain directly impact on
depressive symptoms in patients with dementia? We
found that the composite mood syndrome, which
includes NPSs like depression, apathy, irritability,
night-time behaviours, and appetite and eating disor-
ders responded to pain treatment in agitated persons
with advanced dementia. Anxiety and irritability, how-
ever, did not beneﬁt signiﬁcantly by pain treatment.
Mood symptoms are common and difﬁcult to manage
in dementia. It is crucial to follow up these results with
a multicenter, parallel-group, double-blind RCT.
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